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Abstract Drug discovery, development and registration
is an expensive and time-consuming process associated
with a high failure rate [Pessetto et al. (Mol Cancer Ther
12:1299–1309, 2013), Woodcock and Woosley (Annu Rev
Med 59:1–12, 2008)]. Drug ‘repurposing’ is the identifi-
cation of new therapeutic purposes for already approved
drugs and is more affordable and achievable than novel
drug discovery [Pessetto et al. (Mol Cancer Ther
12:1299–1309, 2013)]. Auranofin is a drug that is approved
for the treatment of rheumatoid arthritis but is being in-
vestigated for potential therapeutic application in a number
of other diseases including cancer, neurodegenerative dis-
orders, HIV/AIDS, parasitic infections and bacterial in-
fections [Tejman-Yarden et al. (Antimicrob Agents
Chemother 57:2029–2035, 2013)]. The main mechanism of
action of auranofin is through the inhibition of reduction/
oxidation (redox) enzymes that are essential for maintain-
ing intracellular levels of reactive oxygen species. Inhibi-
tion of these enzymes leads to cellular oxidative stress and
intrinsic apoptosis [Pessetto et al. (Mol Cancer Ther
12:1299–1309, 2013), Fan et al. (Cell Death Dis 5:e1191,
2014), Fiskus et al. (Cancer Res 74:2520–2532, 2014),
Marzano et al. (Free Radic Biol Med 42:872–881, 2007)].
Drugs such as auranofin that have already been approved
for human use [Tejman-Yarden et al. (Antimicrob Agents
Chemother 57:2029–2035, 2013)] can be brought into
clinical use for other diseases relatively quickly and for a
fraction of the cost of new drugs.
Key Points
Drug ‘repurposing’ is more affordable and less time-
consuming than novel drug discovery.
Auranofin has potential as a therapy for a number of
diseases including cancer, neurodegenerative
disorders, HIV/AIDS, parasitic infections and
bacterial infections.
1 Introduction
The current system of discovery, development and regis-
tration of new drugs is estimated to cost USD$1.5 billion
and often requires 10–17 years to complete [1]. This ex-
pensive and time-consuming process often results in fail-
ure, with an estimated 70–90 % of drugs failing clinical
trials [2]. Drug ‘repurposing’ is the identification of new
therapeutic applications for drugs that have received US
FDA approval for another purpose. Due to the reduced
length and cost of research and trial phases, drug repur-
posing is more affordable and achievable than novel drug
discovery, with patients gaining access to new therapies
more quickly [1].
One drug that is receiving increasing attention for its
potential to be repurposed is Auranofin, approved for the
treatment of rheumatoid arthritis in 1985 [3]. Auranofin
[2,3,4,6-tetra-o-acetyl-L-thio-b-D-glycopyranp-sato-S-(tri-
ethyl-phosphine)-gold] has a well-known toxicity profile
and is considered safe for human use [4–6]. It is a
gold(I) compound with phosphine and thiol ligands in a
linear arrangement (Fig. 1). After oral dosing, 15–25 % of
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the drug can be detected in the plasma, where it binds
predominantly to albumin [6–8]. Most of this is absorbed
via the gastrointestinal tract within the first 20 min [9], and
within 1–2 h a peak plasma concentration of 6–9 lg/
100 mL is reached. The plasma half-life is 15–25 days
with almost total body elimination after 55–80 days [7, 8].
Auranofin is mainly excreted in the faeces (85 %), with
only 15 % appearing in the urine [6, 10]. Just 0.4 % of the
administered dose is concentrated in the kidneys [6].
Rheumatoid arthritis is characterised by persistent in-
flammation and joint swelling leading to functional dis-
ability [6]. Auranofin was prescribed for the treatment of
rheumatoid arthritis as a disease-modifying antirheumatic
drug (DMARD) [6], and was able to slow disease progres-
sion by suppressing inflammation and stimulating cell-me-
diated immunity. Auranofin also inhibits phagocytosis by
macrophages and the release of lysosomal enzymes and
antibodies involved in cytotoxicity reactions [10, 11].
Although considered safer than the injectable gold coun-
terparts (myochrysine, anochrysine, allochrysine and sol-
ganol) [6], aurnaofin was found to be less effective than
other DMARDs, such as methotrexate, which led to a de-
cline in the clinical use of auranofin [8]. Although DMARDs
are still the primary treatment option for rheumatoid
arthritis, there has been rapid development in biological
therapies that inhibit cytokine targets, thus suppressing the
pro-inflammatory cascade associated with rheumatoid
arthritis. These drugs include tumour necrosis factor (TNF)-
a inhibitors such as the monoclonal antibodies infliximab,
adalimumab, the TNF-a-receptor fusion protein etanercept,
and the interleukin (IL)-1 inhibitor anakinra [11].
The decline in the use of auranofin for the treatment of
rheumatoid arthritis may be due, in part, to its adverse
effects, most of which are associated with long-term use for
chronic disease. The most common adverse effects are
gastrointestinal complaints such as loose stools, abdominal
cramping and watery diarrhoea, which can develop in the
early months of treatment. The development of loose stools
occurs in 40 % of patients, while watery diarrhoea is
reported in just 2–5 % of patients, and in most cases these
symptoms were alleviated by reducing or splitting the dose
[7, 8]. These symptoms are associated with changes in
intestinal fluid movement and the net secretion of sodium,
potassium, chloride and bicarbonate, as well as changes in
the absorption of glucose and mannitol [12, 13]. Other
adverse effects include skin irritations or rash, which occur
in 20 % of patients within the first year of treatment, as
well as stomatitis and mouth ulcerations, which occur in
1–12 % of patients and are often concomitant with skin
rashes. Conjunctivitis occurs in 4 % of patients, proteinuria
occurs in up to 5 % of patients, and there have been some
reports of thrombocytopenia and bone marrow suppression,
but these are extremely rare [7, 8].
Auranofin may no longer be the drug of choice for
rheumatoid arthritis, but there is potential for new appli-
cations in the treatment of some cancers, parasitic infec-
tions, bacterial infections, HIV and even neurodegenerative
disorders such as Parkinson’s disease and Alzheimer’s.
Table 1 provides a list of studies investigating the repur-
posing of auranofin for diseases other than rheumatoid
arthritis.
2 Mechanisms of Action
The main mechanism of action of auranofin is through the
inhibition of reduction/oxidation (redox) enzymes such as
thioredoxin reductase (TrxR). The thiol ligand contained in
auranofin has a high affinity for thiol and selenol groups, to
which it forms stable, and irreversible, adducts [14]. Redox
enzymes such as TrxR are essential to many cellular pro-
cesses, particularly in maintaining the intracellular levels
of reactive oxygen species (ROS) [1, 14–16]. Controlling
the level of ROS to prevent the resulting DNA damage is
critical for the survival of all cell types, including cancer
cells, parasites and memory T cells that harbour proviral
HIV DNA. These particular cell types all over-express
redox enzymes, which increases the affinity of auranofin
towards these cells [1, 3, 14–22]. Inhibition of redox en-
zymes alters the redox state of the cell, which can lead to
increased production of hydrogen peroxide and ROS that
causes cellular oxidative stress and ultimately intrinsic
apoptosis [1, 14–16].
Auranofin is particularly potent for selenoproteins and
selenium-dependent enzymes because it also has a high
affinity towards inorganic selenium in the form of selenide
(HSe-). Auranofin and HSe- are able to form a stable
adduct through displacement of the sulphur in the auranofin
thiol with the Se in the HSe- [23], resulting in a hydrogen
sulphide by-product and the auranofin selenium compound.
Selenoproteins such as TrxR in mammalian cells have been
identified as a potential drug target for cancer [14], while
Fig. 1 The chemical structure of auranofin
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selenoproteins involved in Stickland reactions in amino
acid-fermenting bacteria have been identified as a potential
drug target for these bacterial infections [23, 24].
An alternate mechanism of action of auranofin is
through inhibiting the ubiquitin–proteasome system (UPS)
in cancer cells. Studies have shown that many different
cancers, such as colon, prostate and leukaemia, rely on the
UPS system more heavily than non-cancer cells [25, 26].
The UPS system is involved in many cellular processes,
including cell cycle regulation, protein degradation, gene
expression and DNA repair. The 26S proteasome consists
of two parts: the 20S proteasome peptidase and the 19S
proteasome-associated deubiquitinase (DUBs) [25, 26]. Liu
et al. [26] reported that inhibiting either part of the 26S
proteasome induced apoptosis, and that the current treat-
ment for relapsed myeloma and mantle cell lymphoma,
bortezomib/Velcade, targeted the 20S proteasome pepti-
dase. Auranofin, on the other hand, inhibited the DUBs,
suggesting that these two drugs inhibited UPS by different
mechanisms. The authors suggested that the activity of
auranofin may be due to its Au–S bond, shown in Fig. 1, as
blocking this active site prevents auranofin from inhibiting
DUBs and inducing apoptosis.
3 Cancer
Cancer is a major public health problem in many parts of
the world, with the estimated number of new cases in the
USA every year in excess of 1,600,000 [27]. Although
death rates in the USA are declining by just over 1 %
annually, there are still more than 500,000 deaths [27]. The
development of resistance to the current first-line
chemotherapeutics by cancer cells is one of the major
reasons for clinical failure of therapy and has prompted the
search for new anti-cancer therapies. Auranofin is effective
against cancer cells by two mechanisms of action. The first
is through inhibition of mammalian TrxR (mTrxR), which
is a critical regulator of redox balance in the cytosol and in
the mitochondria. Auranofin is a potent inhibitor of mTrxR
because of the presence of selenium in the form of se-
lenocysteine in mTrxR [1, 14–16]. The second is through
Table 1 Diseases for which
auranofin is being investigated
as a potential treatment
Disease References
Cancer
Leukaemia and lymphoma [15, 25, 28, 29]
Chronic lymphocytic leukaemia (CLL)
Small lymphocytic lymphoma (SLL)
Prolymphocytic lymphoma (PLL)
Chronic myelogenous leukaemia (CML)
Human ovarian cancer (cisplatin-sensitive and cisplatin-resistant) [16]
Gastrointestinal stromal tumour (GIST; imatinib-resistant) [14]
Neurodegenerative disorders
Alzheimer’s and Parkinson’s disease [5, 9]
HIV/AIDS [21, 31]
Parasitic infections
Trypanosomatids [17, 19, 33]
Trypanosoma spp.
Leishmania spp.
Platyhelminthes [22, 34, 35]
Schistosoma spp.
Echinococcus granulosus
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inhibition of the UPS system by targeting DUBs, which are
involved in cell cycle regulation, protein degradation, gene
expression and DNA repair [25, 26]. Both these mechan-
isms of action induce apoptosis.
In 1985, Mirabelli et al. [28] showed that auranofin had
potent in vitro cytotoxic activity against a number of tu-
mour cell lines including P388 mouse leukaemia. They
went on to demonstrate that auranofin also had in vivo
activity against P388 leukaemia with a maximum cell kill
of 0.6 log at a single daily dose of 8 mg/kg given via
intraperitoneal injection. Since this time there have been
numerous in vitro and in vivo studies focusing on the anti-
tumour activity of auranofin. Marzano et al. [16] were able
to show that auranofin induced apoptosis in vitro in both
cisplatin-sensitive (2008) and cisplatin-resistant (C13*)
human ovarian cancer cells, observing that auranofin is
more effective at decreasing cell viability than cisplatin.
Pessetto et al. [1] have also demonstrated the apoptotic
activity of auranofin against tumour cells in vitro, this time
in gastrointestinal stromal tumour (GIST) cells (GIST-T1),
including imatinib-resistant GIST. There have also been
studies focusing on chronic lymphocytic leukaemia (CLL),
which is associated with high rates of relapse and resis-
tance to treatments. Fiskus et al. [15] reported that aura-
nofin showed apoptotic activity against cultured and
patient-derived CLL cells. Auranofin is currently in a phase
I/II clinical trial for the treatment of CLL, small lympho-
cytic lymphoma (SLL) and prolymphocytic lymphoma
(PLL) (NCT01419691) [29]. Fan et al. [14] not only
demonstrated the in vitro and in vivo apoptotic activity of
auranofin against non-small-cell lung cancer (A549 human
lung adenocarcinoma) but also investigated the enhance-
ment of this activity through the addition of selenocysteine,
a natural inhibitor of TrxR, theorising that selenocysteine
competes with thioredoxin, the substrate for TrxR.
While investigating its other mechanism of action
against cancer cells, Chen et al. demonstrated that aura-
nofin had a strong cytotoxic effect against chronic myel-
ogenous leukaemia (CML) expressing the fusion
oncoprotein Bcr-Abl. Further to this they showed that au-
ranofin could overcome resistance to the tyrosine kinase
inhibitor imatinib mesylate, which is the current treatment
for chronic-phase CML. Resistance to imatinib mesylate is
caused by point mutations in the Bcr-Abl gene, and while
new tyrosine kinase inhibitors such as nolotinib, dasatinib
and INNO-406 are effective against most of these muta-
tions, they are not effective against the most common, a
T315I missense mutation which accounts for 20 % of all
point mutations of Bcr-Abl. Auranofin is able to inhibit
expression of Bcr-Abl and induce caspase activation that
cleaves Bcr-Abl, leading to downregulation of Bcr-Abl and
reduced cell proliferation [25]. Independent of this, aura-
nofin also induces apoptosis by inhibiting DUBs [25, 26].
4 Neurodegenerative Disorders
Neurodegenerative disorders such as Alzheimer’s and
Parkinson’s disease have both been linked to inflammation
in the CNS [5, 9]. This inflammation is driven by the ac-
tivation of the glial cells, microglia and astrocytes, which
when activated release neurotoxins and inflammatory me-
diators. When combined with a deficiency in neurotrophic
factors, these neurotoxins and inflammatory mediators can
harm the nearby neurons, contributing to progression of
neurodegenerative disorders [5, 9]. Reducing the inflam-
mation, decreasing the release of neurotoxins or increasing
the release of neurotrophic factors could reduce neuronal
loss, potentially slowing the progression of these diseases
[5, 9]. Current treatments for neurodegenerative disorders
include antioxidants and metal–protein attenuating com-
pounds (MPACs) such as desferrioxamine for Alzheimer’s
disease. These treatments target the abnormal metal–pro-
tein interactions and the associated oxidative stress that
also contribute to neuron degeneration [30], but not the
inflammation driven by activated glial cells [5].
Auranofin acts as an anti-inflammatory, altering cyto-
kine levels by increasing IL-8 and reducing IL-6 secretion
from lipopolysaccharide-stimulating human monocytes.
Auranofin also induces the anti-inflammatory enzyme he-
me oxygenase (HOX)-1 in the human monocyte cell line
THP-1 cells, protecting neuronal cells from oxidative stress
induced by hydrogen peroxide [5]. In addition to this,
Madeira et al. [5] demonstrated that auranofin can inhibit
the neurotoxic effects of stimulated primary human astro-
cytes and U-373 astrocyte cells toward human neuronal
cells in low micromolar concentrations (0.1–5 lmol/L).
They then demonstrated that auranofin can also inhibit the
neuronal cells from the microglia toxins TNF-a and nitric
oxide [9]. The authors suggested that auranofin may have
neuroprotective activity in addition to the previously de-
scribed anti-inflammatory activity [5, 9], although the
mechanisms for this are not known. Auranofin has been
shown to reach the CNS in low micromolar concentrations
(0.2–5 lmol/L), indicating that enough auranofin can cross
the blood–brain barrier to have similar in vivo protective
effects to those seen in vitro [9].
5 HIV/AIDS
Complete elimination of HIV is a distant goal, with current
treatment goals being a functional cure that will effectively
control the virus within the host. An ideal functional cure is
one that is able to be withdrawn for prolonged periods
without risk of the virus rebounding to pre-therapy levels
[31]. People with HIV/AIDS need lifelong antiretroviral
(ARV) therapy as HIV infection will persist despite this
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treatment, with viral titres increasing upon withdrawal.
There are also viral reservoirs that are invulnerable to ARV
therapy, such as the central and transitional memory T cells
(TCM and TTM, respectively) [21, 31]. TCM and TTM are
long-lived and carry dormant proviral DNA copies of the
virus integrated into the genome. These DNA copies can-
not be targeted by either the immune system or current
drug-based therapies. Auranofin has been shown to induce
cell death in TCM and TTM [21]. Studies using combined
ARV and auranofin therapy in rhesus macaques infected
with the HIV simian homologue SIVmac251 have been
able to maintain the reduced viral titre long-term after
treatment was withdrawn. The effects of auranofin on the
memory T cells were not associated with any detectable
immune impairment [21]. Another study, also using the
macaque primate model, added buthionine sulfoimine
(BSO) to the ARV/auranofin therapy, which is an inhibitor
of glutathione synthesis. This combination therapy resulted
in long-term reduction in the post-viral set point larger than
that of the ARV/auranofin therapy described above [31].
Auranofin is able to induce cell death in TCM and TTM
in the same way it does in cancer cells and some parasites,
by inhibiting TrxR activity. Inhibition of TrxR leads to
increased oxidative stress in the cells, which activates the
redox-sensitive apoptosis pathways [21]. BSO inhibits the
synthesis of glutathione, another intracellular antioxidant.
Both auranofin and BSO have been shown to induce par-
tially selective killing of infected cells in vitro [31]. The
combination of two drugs that induce redox-sensitive cell
death by targeting different cellular targets could ensure
more widespread death of HIV-infected memory T cells,
resulting in longer periods of reduced viral titre following
withdrawal of treatment.
6 Parasitic Infections
Many parasitic infections are classified as Neglected Tro-
pical Diseases (NTDs) by the Centers for Disease Control
and Prevention (CDC) as there is a lack of attention by the
global public health community [32]. NTDs affect one-
sixth of the world’s population [32], with malaria (Plas-
modium falciparum) alone killing approximately 660,000
people each year [22]. NTDs are more prevalent among the
world’s poorest peoples, who often have limited access to
adequate healthcare. Further compounding this problem is
the development of drug resistance to the current treat-
ments [32]. Clearly there is a need for alternative therapies
that are both inexpensive and easily attainable.
Like cancer cells, parasites need to maintain cellular
redox balance, and rely on redox enzymes such as TrxR,
the thioredoxin–glutathione reductase system (TGR) and
typanthione reductase (TypR) to prevent an accumulation
of hydrogen peroxide and ROS in the cytosol and mito-
chondria. Auranofin is able to inhibit the action of the
TrxR, TGR or TypR enzymes, hence allowing oxidative
stress to damage the parasites [3, 17–20, 22]. The effects of
auranofin have been studied on a number of parasitic
species including Giardia lamblia [3, 18], Entamoeba
histolytica [18], Trypanosoma brucei [33], Leishmania in-
fantum [17, 19], L. major [19], Schistosoma mansoni [22,
34, 35], Echinococcus granulosus [34], Toxoplasmsa
gondii [36] and P. falciparum [2, 4].
Debnath et al. [18] investigated the effects of auranofin
on G. lamblia and E. histolytica, which cause the diar-
rhoeal diseases giardia and amebasis, respectively. There
are currently no vaccines or prophylactics for either of
these diseases, and first-line therapy is usually nitramida-
zoles such as metronidazole. E. histolytica trophozites are
able to adapt to therapeutic concentrations of metronida-
zole and there is clinical evidence for metronidazole re-
sistance in G. lamblia. Debnath et al. [18] demonstrated
that E. histolytica trophozites are more sensitive to killing
by hydrogen peroxide and ROS when exposed to auranofin
due to inhibition of TrxR. Similar results have been de-
scribed for G. lamblia in both this study [3] and another by
Tejman-Yarden et al., who investigated the effects of au-
ranofin on metronidazole-resistant G. lamblia [18].
Trypanosomatids are an order of protozoan parasites
responsible for diseases such as sleeping sickness, South
American Chagas disease and leishmaniasis [17, 33].
Sleeping sickness and Chagas disease are caused by Try-
panosoma spp. Annually 300,000–500,000 people are in-
fected with sleeping sickness and 40,000 people die from it,
while Chagas disease affects 16–18 million people [33].
Leishmaniasis is caused by Leishmania spp. and is endemic
in 98 countries with approximately 2 million new cases
annually [17]. Treatment for sleeping sickness depends on
the stage of the disease. First-stage treatments such as
pentamidine and suramin have a relatively lower toxicity
and are easier to administer. Second-stage drugs include
melarsoprol, which is fatal in 3–10 % of cases, and eflor-
nethine, which is less toxic than melarsoprol but requires a
strict and difficult to apply regimen and is only effective
against Trypanosoma brucei gambiense, not T. b. rhode-
siense [37]. Chagas disease is treated with benznidazole or
nifurtimox, which are both 100 % effective for the acute
phase of the disease, but less so for the chronic phase [38].
Treatment for leishmaniasis can range from sodium sti-
bogluconate and amphotericin B to miltefosin and paro-
momycin; however, these treatments have detrimental
effects or pharmacological liabilities that result in treatment
failure or relapse of disease. There is no optimal therapy and
the response to any of these drugs is inconsistent. As a
result, many cases of leishmaniasis go untreated, leaving the
patient disfigured due to the characteristic lesions caused by
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these parasites [17]. Lobanov et al. reported high rates of
conservation of selenoproteins in Trypanosoma and Leish-
mania species. They also demonstrated that auranofin was
highly toxic for both bloodstream and procyclic stages of T.
b. brucei, concluding that inhibiting redox selenoproteins
may be effective against these types of infections [33].
Leishmania spp. utilise a typanothione-based system to re-
duce oxidative stress and to synthesise and utilise sper-
midine, which is essential for the parasites’ growth and
survival [19]. Ilari et al. [19] demonstrated that auranofin
could induce a dose-dependent anti-proliferative effect on
L. infantum and L. major promastigotes. Similar results
were found by Sharlow et al. [17], who studied the effect of
auranofin on L. major and L. amazonensis. Both of these
studies investigated the ability of auranofin to inhibit TypR,
leading to an apoptotic-like response in promastigotes
[17, 19].
Parasites from the phylum Playhelminth are responsible
for diseases such as schistomanasis and hydatid. The cur-
rent treatment for these infections is praziquantel, which is
still successful in most cases [34]. Continued use of
praziquantel has seen the emergence of drug resistance,
which is of serious concern since it is the only drug that is
readily available for large-scale treatment of these diseases
[22, 34]. Platyelminths such as Schistosoma mansoni and
Echinciccus granulosis rely on TGR to prevent oxidative
stress caused by ROS [22]. Studies by Kuntz et al. [35],
Bonilla et al. [34] and Caroli et al. [22] have shown that
auranofin can induce oxidative stress and inhibit growth in
both these organisms by inhibiting the activity of TGR.
P. falciparum causes malaria, a blood infection that kills
660,000 people annually [22]. The treatment for malaria is
chloroquine, but there has been an emergence of resistance
to this drug [22]. P. falciparum relies on a TrxR and a
glutathione reductase to maintain redox homeostastis [4,
22]. Auranofin has been shown to inhibit the activity TrxR
in P. falciparum, leading to severe oxidative stress and
inhibition of growth [4]. Another parasite from the phylum
Apicomplexa is Toxoplasma gondii, which affects an es-
timated two-thirds of the world population. There are very
few treatments against this parasite, most of which are only
active against the active lifecycle stage (tachyozoite) and
are unable to eradicate the parasite from the human body,
leaving the host susceptible to recurrence. Infection with T.
gondii can cause long-term complications such as blind-
ness or neurological abnormalities, due to the parasite’s
fondness for the brain and retinas [36]. Auranofin has been
shown to reduce parasitic replication in vitro and parasitic
load in vivo. In a chicken embryo model of acute
toxoplasmosis, a single dose of 1 mg/kg of estimated body
weight was able to prevent death. Although the authors of
this study are yet to determine the exact molecular target,
they do speculate that auranofin acts on one of the multiple
antioxidant enzymes used to maintain redox homeostasis in
T. gondii [36].
7 Bacterial Infections
Antibacterial (antibiotic) resistance is one of the greatest
public health crises facing us today. Without effective
antibacterials it will not be possible to care for premature
infants or the critically ill, cancer patients would not be
able to receive chemotherapy and many surgeries, espe-
cially organ transplants, would carry too high a risk of
untreatable infection [39]. Although there is an urgent need
for novel antimicrobials, pharmaceutical companies are
withdrawing from the antibacterial market, putting an-
tibacterial development at a standstill [39]. It makes sense
to repurpose old drugs with potential antimicrobial activity
for the treatment of antibacterial-resistant infections. Au-
ranofin has shown antimicrobial activity against a number
of bacterial pathogens including Staphylococcus aureas,
Clostridium difficile, Treponema denticola and Entero-
coccus faecalis.
C. difficile is a Gram-positive, anaerobic hospital-ac-
quired infection (HAI), the symptoms of which range from
diarrhoea to severe and life-threatening pseudomembra-
nous colitis [23]. The ability of this pathogen to cause
widespread disease coupled with its potential for antibac-
terial resistance prompted the CDC to raise its threat level
to urgent [40]. T. denticola is one of the primary pathogens
responsible for periodontitis, one of the major causes of
adult tooth loss. Both of these bacteria rely on Stickland
reactions performed by the selenoprotein glycine reductase
for energy. Auranofin is able to inhibit the activity of
glycine reductase by forming a stable bond with inorganic
selenium, disrupting selenium metabolism and the syn-
thesis of selenocysteine. Without selenocysteine, these
bacteria cannot synthesise glycine reductase, and are
therefore unable to reduce glycine for energy production
[23, 24]. C. difficile also uses the selenoprotein proline
reductase for energy production. The activity of proline
reductase is also inhibited by auranofin in a similar fashion
to glycine reductase [41]. Auranofin has been shown to
inhibit the growth of C. difficile and T. denticola in vitro at
low micromolar concentrations [23, 24].
Methicillin-resistant S. aureas (MRSA) infections are
responsible for over 80,000 infections annually in the USA
[40]. The first-line treatment for MRSA is vancomycin, but
with the emergence of vancomycin-resistant S. aureas
(VRSA) there is an urgent need for another alternative
antibacterial. Auranofin has shown activity against S. au-
reas in the nanomolar range (150–300 nM), including ac-
tivity against both MRSA and VRSA. The mechanism of
growth inhibition is not yet known [42].
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E. faecalis is an HAI that produces biofilms during in-
fection, usually in the bladder as the result of catherisation,
but can also produce vegetative growths on heart tissue
[43]. Vancomycin-resistant Enterococcus spp. (VRE) are a
serious threat to public health, as there are very few
treatment options left after vancomycin. E. faecalis infec-
tions make up approximately 9 % of the 20,000 VRE HAIs
seen annually in the USA [40]. Biofilm production in E.
faecalis has been linked to a putative xanthine dehydro-
genase (EF2570), a labile selenoprotein that is upregulated
in the presence of uric acid, selenium and molybdenum.
There is evidence that this xanthine dehydrogenate is
necessary for extracellular superoxide and hydrogen per-
oxide production, which correlated with biofilm density.
Reducing selenium bioavailability inhibits the activity of
xanthine dehydrogenase, resulting in a reduction in biofilm
density. Auranofin was able to inhibit the biofilm formation
of E. faecalis at a concentration of 1 lmol/L [43].
8 Summary
Drug repurposing can provide new therapeutic options for a
vast number of diseases where current therapies are failing
or are inadequate. Multidrug resistance is becoming prob-
lematic in diseases such as cancer, parasitic infections and
bacterial infections, leading to poor clinical outcomes.
Current options for diseases such as HIV require ongoing
therapy, while the treatment options for neurodegenerative
disorders such as Alzheimer’s and Parkinson’s disease
target metal homeostasis and related oxidative stress but
not the inflammation.
Auranofin has the potential to be repurposed for a lot of
diseases. Auranofin has a high affinity for thiols and seleno-
proteins and is able to inhibit enzymes that reduce intracel-
lular ROS such as TrxR, which have been shown to be an
effective therapeutic target for cancer, parasitic infections and
HIV. The high affinity of auranofin to selenium and seleno-
proteins disrupts bacterial selenium metabolism, a potential
therapeutic target for the hospital-acquired C. difficile infec-
tion and drug-resistant infections such as MRSA and VRE.
Further to this, auranofin has been described as having anti-
inflammatory and neuroprotective activity that could prove
useful in the treatment of neurodegenerative disorders.
New drug discovery is an expensive and risky endeav-
our. Coupled with reduced funding and support from
government and industry bodies, particularly in the areas of
antimicrobials and NTDs, the drug discovery pipeline is
slowing down. It makes sense to look to old drugs that have
already passed clinical trials and received FDA approval
for other diseases. These drugs can be brought into clinical
use for other diseases relatively quickly and for a fraction
of the cost of new drugs.
Acknowledgments The authors have no conflict of interest to
declare.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and the source are credited.
References
1. Pessetto ZY, Weir SJ, Sethi G, Broward MA, Godwin AK. Drug
repurposing for gastrointestinal stromal tumor. Mol Cancer Ther.
2013;12(7):1299–309. doi:10.1158/1535-7163.mct-12-0968.
2. Woodcock J, Woosley R. The FDA critical path initiative and its
influence on new drug development. Annu Rev Med. 2008;59:1–12.
3. Tejman-Yarden N, Miyamoto Y, Leitsch D, Santini J, Debnath A,
Gut J, et al. A reprofiled drug, auranofin, is effective against
metronidazole-resistant Giardia lamblia. Antimicrob Agents
Chemother. 2013;57(5):2029–35.
4. Sannella AR, Casini A, Gabbiani C, Messori L, Bilia AR, Vin-
cieri FF, et al. New uses for old drugs. Auranofin, a clinically
established antiarthritic metallodrug, exhibits potent antimalarial
effects in vitro: mechanistic and pharmacological implications.
FEBS Lett. 2008;582(6):844–7.
5. Madeira JM, Renschler CJ, Mueller B, Hashioka S, Gibson DL,
Klegeris A. Novel protective properties of auranofin: inhibition of
human astrocyte cytotoxic secretions and direct neuroprotection.
Life Sci. 2013;92(22):1072–80.
6. Messori L, Marcon G. Gold complexes in the treatment of
rheumatoid arthritis. Met Ions Biol Syst. 2004;41:279–304.
7. Kean WF, Kean IR. Clinical pharmacology of gold. Inflam-
mopharmacology. 2008;16(3):112–25.
8. Kean WF, Hart L, Buchanan WW. Auranofin. Br J Rheumatol.
1997;36(5):560–72.
9. Madeira JM, Bajwa E, Stuart MJ, Hashioka S, Klegeris A. Gold
drug auranofin could reduce neuroinflammation by inhibiting
microglia cytotoxic secretions and primed respiratory burst.
J Neuroimmunol. 2014;276(1–2):71–9.
10. Walz DT, DiMartino MJ, Griswold DE, Intoccia AP, Flanagan
TL. Biologic actions and pharmacokinetic studies of auranofin.
Am J Med. 1983;75(6A):90–108.
11. Doan T, Massarotti E. Rheumatoid arthritis: an overview of new
and emerging therapies. J Clin Pharmacol. 2005;45(7):751–62.
12. Behrens R, Devereaux M, Hazleman B, Szaz K, Calvin J, Neale
G. Investigation of auranofin-induced diarrhoea. Gut. 1986;27(1):
59–65.
13. Ammon HV, Fowle SA, Cunningham JA, Komorowski RA,
Loeffler RF. Effects of auranofin and myochrysine on intestinal
transport and morphology in the rat. Gut. 1987;28(7):829–34.
14. Fan C, Zheng W, Fu X, Li X, Wong YS, Chen T. Enhancement of
auranofin-induced lung cancer cell apoptosis by selenocystine, a
natural inhibitor of TrxR1 in vitro and in vivo. Cell Death Dis.
2014;5:e1191.
15. Fiskus W, Saba N, Shen M, Ghias M, Liu J, Gupta SD, et al.
Auranofin induces lethal oxidative and endoplasmic reticulum
stress and exerts potent preclinical activity against chronic lym-
phocytic leukemia. Cancer Res. 2014;74(9):2520–32.
16. Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, Rigobello
MP. Inhibition of thioredoxin reductase by auranofin induces
apoptosis in cisplatin-resistant human ovarian cancer cells. Free
Radic Biol Med. 2007;42(6):872–81.
17. Sharlow ER, Leimgruber S, Murray S, Lira A, Sciotti RJ,
Hickman M, et al. Auranofin is an apoptosis-simulating agent
Auranofin: Repurposing of an Old Drug 19
with in vitro and in vivo anti-leishmanial activity. ACS Chem
Biol. 2014;9(3):663–72.
18. Debnath A, Ndao M, Reed SL. Reprofiled drug targets ancient
protozoans. Gut Microbes. 2013;4(1):66–71.
19. Ilari A, Baiocco P, Messori L, Fiorillo A, Boffi A, Gramiccia M,
et al. A gold-containing drug against parasitic polyamine meta-
bolism: the X-ray structure of trypanothione reductase from
Leishmania infantum in complex with auranofin reveals a dual
mechanism of enzyme inhibition. Amino Acids. 2012;42(2–3):
803–11.
20. Watkins RR, Eckmann L. Treatment of giardiasis: current status
and future directions. Curr Infect Dis Rep. 2014;16(2):396.
21. Chirullo B, Sgarbanti R, Limongi D, Shytaj IL, Alvarez D, Das B,
et al. A candidate anti-HIV reservoir compound, auranofin, exerts
a selective ‘anti-memory’ effect by exploiting the baseline ox-
idative status of lymphocytes. Cell Death Dis. 2013;4:e944.
22. Caroli A, Simeoni S, Lepore R, Tramontano A, Via A. Investi-
gation of a potential mechanism for the inhibition of SmTGR by
auranofin and its implications for Plasmodium falciparum inhi-
bition. Biochem Biophys Res Commun. 2012;417(1):576–81.
23. Jackson-Rosario S, Cowart D, Myers A, Tarrien R, Levine RL,
Scott RA, et al. Auranofin disrupts selenium metabolism in
Clostridium difficile by forming a stable Au–Se adduct. J Biol
Inorg Chem. 2009;14(4):507–19.
24. Jackson-Rosario S, Self WT. Inhibition of selenium metabolism
in the oral pathogen Treponema denticola. J Bacteriol. 2009;
191(12):4035–40.
25. Chen X, Shi X, Zhao C, Li X, Lan X, Liu S, et al. Anti-rheumatic
agent auranofin induced apoptosis in chronic myeloid leukemia
cells resistant to imatinib through both Bcr/Abl-dependent and -
independent mechanisms. Oncotarget. 2014;5(19):9118–32.
26. Liu N, Li X, Huang H, Zhao C, Liao S, Yang C, et al. Clinically
used antirheumatic agent auranofin is a proteasomal deubiquiti-
nase inhibitor and inhibits tumor growth. Oncotarget. 2014;5(14):
5453–71.
27. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA
Cancer J Clin. 2012;62(1):10–29.
28. Mirabelli CK, Johnson RK, Sung CM, Faucette L, Muirhead K,
Crooke ST. Evaluation of the in vivo antitumor activity and
in vitro cytotoxic properties of auranofin, a coordinated gold
compound, in murine tumor models. Cancer Res. 1985;45(1):
32–9.
29. University of Kansas. Phase I and II study of auranofin in chronic
lymphocytic leukemia (CLL). [ClinicalTrials.gov identifier
NCT01419691]. US National Institutes of Health, ClinicalTri-
als.gov. http://clinicaltrials.gov.
30. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases
and oxidative stress. Nat Rev Drug Discov. 2004;3(3):205–14.
31. Shytaj IL, Chirullo B, Wagner W, Ferrari MG, Sgarbanti R, Corte
AD, et al. Investigational treatment suspension and enhanced
cell-mediated immunity at rebound followed by drug-free re-
mission of simian AIDS. Retrovirology. 2013;10(1):71.
32. CDC’s neglected tropical disease program. Atlanta: Center for
Global Health, Division of Parasitic diseases and Malaria; 2014.
http://www.cdc.gov/globalhealth/ntd/resources/ntd_factsheet.pdf.
Accessed 2 Feb 2015.
33. Lobanov AV, Gromer S, Salinas G, Gladyshev VN. Selenium
metabolism in Trypanosoma: characterization of selenopro-
teomes and identification of a Kinetoplastida-specific selenopro-
tein. Nucleic Acids Res. 2006;34(14):4012–24.
34. Bonilla M, Denicola A, Novoselov SV, Turanov AA, Protasio A,
Izmendi D, et al. Platyhelminth mitochondrial and cytosolic re-
dox homeostasis is controlled by a single thioredoxin glutathione
reductase and dependent on selenium and glutathione. J Biol
Chem. 2008;283(26):17898–907.
35. Kuntz AN, Davioud-Charvet E, Sayed AA, Califf LL, Dessolin J,
Arner ES, et al. Thioredoxin glutathione reductase from Schis-
tosoma mansoni: an essential parasite enzyme and a key drug
target. PLoS Med. 2007;4(6):e206.
36. Andrade RM, Chaparro JD, Capparelli E, Reed SL. Auranofin is
highly efficacious against Toxoplasma gondii in vitro and in an
in vivo experimental model of acute toxoplasmosis. PLoS Negl
Trop Dis. 2014;8(7):e2973.
37. World Health Organisation (WHO). Trypanosomiasis, human
African (sleeping sickness). Fact sheet no. 259. 2014. http://www.
who.int/mediacentre/factsheets/fs259/en/. Accessed 14 Jan 2015.
38. World Health Organisation (WHO). Chagas disease (American
trypanosomiasis). Fact sheet no. 340. 2014. http://www.who.int/
mediacentre/factsheets/fs340/en/. Accessed 14 Jan 2015.
39. Infectious Diseases Society of America. Combating antimicrobial
resistance: policy recommendations to save lives. Clin Infect Dis.
2011;52(suppl 5):S397–428.
40. Antibiotic resistant threats in the United States. US Department
of Health and Human Services, Centers for Disease Control and
Prevention. 2013. http://www.cdc.gov/drugresistance/threatreport-
2013/pdf/ar-threats-2013-508.pdf. Accessed 27 Nov 2014.
41. Jackson S, Calos M, Myers A, Self WT. Analysis of proline
reduction in the nosocomial pathogen Clostridium difficile.
J Bacteriol. 2006;188(24):8487–95.
42. Hokai Y, Jurkowicz B, Fernandez-Gallardo J, Zakirkhodjaev N,
Sanau M, Muth TR, et al. Auranofin and related heterometallic
gold(I)-thiolates as potent inhibitors of methicillin-resistant
Staphylococcus aureus bacterial strains. J Inorg Biochem. 2014;
138C:81–8.
43. Srivastava M, Mallard C, Barke T, Hancock LE, Self WT. A
selenium-dependent xanthine dehydrogenase triggers biofilm
proliferation in Enterococcus faecalis through oxidant produc-
tion. J Bacteriol. 2011;193(7):1643–52.
20 C. Roder, M. J. Thomson
